Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Aligos Therapeutics (ALGS) Other Gross PP&E Adjustments (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Other Gross PP&E Adjustments readings, the most recent being $9.8 million for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 28.35% to $9.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.8 million, a 28.35% increase, with the full-year FY2025 number at $9.8 million, up 28.35% from a year prior.
  • Other Gross PP&E Adjustments hit $9.8 million in Q4 2025 for Aligos Therapeutics, down from $10.9 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $10.9 million in Q3 2025 to a low of $3.4 million in Q4 2021.
  • Median Other Gross PP&E Adjustments over the past 5 years was $7.1 million (2023), compared with a mean of $7.1 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: plummeted 33.13% in 2021 and later soared 60.83% in 2024.
  • Aligos Therapeutics' Other Gross PP&E Adjustments stood at $3.4 million in 2021, then surged by 34.74% to $4.6 million in 2022, then rose by 2.38% to $4.7 million in 2023, then surged by 60.83% to $7.6 million in 2024, then increased by 28.35% to $9.8 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were $9.8 million (Q4 2025), $10.9 million (Q3 2025), and $10.2 million (Q2 2025) per Business Quant data.